Hutchmed (China) Limited
Biopharmaceutical firm developing targeted therapies for cancer and immune diseases.
HCM | HKEX
Overview
Corporate Details
- ISIN(s):
- KYG4672N1198 (+1 more)
- LEI:
- 2138006X34YDQ6OBYE79
- Country:
- Hong Kong
- Address:
- LEVEL 18, THE METROPOLIS TOWER, KOWLOON
- Website:
- https://www.hutch-med.com/
- Sector:
- Manufacturing
Description
Hutchmed is a commercial-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapeutics and immunotherapies. The company operates a fully integrated platform, advancing a pipeline of novel drug candidates for the treatment of cancer and immunological diseases. Its research and development strategy focuses on creating highly selective and potent therapies engineered to improve drug exposure and reduce off-target toxicities. Hutchmed has multiple internally discovered medicines approved and marketed for various oncology and immunology indications, supported by a global commercialization infrastructure.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-03-23 09:30 |
2021 Annual Report and Notice of AGM
|
English | 10.9 KB | ||
| 2022-03-11 10:00 |
Update on Status under HFCAA
|
English | 16.8 KB | ||
| 2022-03-09 09:30 |
Vesting of awards under Long Term Incentive Plan
|
English | 36.4 KB | ||
| 2022-03-07 08:00 |
HUTCHMED Receives $15m Milestone from AstraZeneca
|
English | 42.0 KB | ||
| 2022-03-03 16:30 |
Publication of Form 20-F
|
English | 12.7 KB | ||
| 2022-03-03 13:30 |
Retirement of CEO and appointment of new CEO
|
English | 22.1 KB | ||
| 2022-03-03 13:00 |
Full Year Results and Business Updates
|
English | 1.5 MB | ||
| 2022-03-01 09:30 |
Approval to Commercialize ELUNATE® in Macau
|
English | 27.2 KB | ||
| 2022-02-07 09:30 |
HUTCHMED to Announce 2021 Final Results
|
English | 12.8 KB | ||
| 2022-02-04 10:30 |
Phase Ib/II Combination Study of HMPL-453
|
English | 17.8 KB | ||
| 2022-01-20 08:00 |
HUTCHMED Initiates Phase I Trial of HMPL-653
|
English | 19.3 KB | ||
| 2022-01-19 08:00 |
HUTCHMED Data at ASCO GI Cancers Symposium
|
English | 28.8 KB | ||
| 2022-01-17 10:00 |
Holding(s) in Company
|
English | 54.7 KB | ||
| 2022-01-12 12:00 |
Breakthrough Therapy Designation for HMPL-523
|
English | 22.9 KB | ||
| 2022-01-10 08:00 |
HUTCHMED Initiates Phase I Study of HMPL-760
|
English | 22.8 KB |
Automate Your Workflow. Get a real-time feed of all Hutchmed (China) Limited filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Hutchmed (China) Limited
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Hutchmed (China) Limited via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
